Silence Therapeutics Seeks Approval to Cancel AIM Trading
Silence Therapeutics Seeks Approval to Cancel AIM Trading
By Ian Walker
Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.
Write to Ian Walker at ian.walker@wsj.com
By Ian Walker
伊恩·沃克(Ian Walker)著
Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
沉默治療公司週五表示，它正在尋求股東批准，取消其在倫敦初級AIM的上市，保留在紐約納斯達克(Nasdaq)的單一上市。
The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
這家醫療公司表示，從AIM退市將增強其美國存托股票的流動性，並增加美國投資者投資該公司的意願。
If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.
該公司表示，如果在11月1日的股東大會上獲得股東批准，AIM的最後一個交易日預計將是11月29日。
Write to Ian Walker at ian.walker@wsj.com
寫信給Ian Walker：ian.walker@wsj.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧